The results of the AFORRD trial were presented at the International Diabetes Federation Congress in Cape Town on Thursday 7th December 2006
A copy of the press release is attached.
DREAM drug washout study results released at IDF WDC2006 Cape Tow
Paraoxonase2 (PON2) Polymorphisms and Development of Renal Dysfunction in Type 2 Diabetes: UKPDS 76
Calle R, McCarthy MI, Banerjee P, Zeggini E, Cull CA, Thorne KI, Wiltshire S, Terra S, Meyer D, Richmond J, Mancuso J, Milos P, Fryburg D, Holman RR
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe
Viberti G, Lachin J, Holman R, Zinman B, Haffner S, Kravitz B, Heise MA, Jones NP, O'Neill MC, Freed MI, Kahn SE, Herman WH for the ADOPT Study Group
Diabetic Medicine 2006;23:1289-129
Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS 73
Wright AD, Cull CA, Macleod KM, Holman RR for the UKPDS Group
Journal of Diabetes and its Complications 2006;20:402-40
Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes
Steven E. Kahn, Bernard Zinman, Steven M...
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials
Christoph Stettler, Sabin Allemann, Peter Jüni, Carole A. Cull, Rury R...
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
David M Nathan, John B Buse, Mayer B Davidson, Robert J Heine, Rury R Holman, Robert Sherwin, Bernard Zinman
Published simultaneously in:
Diabetes Care (2006); 29: 1963-1972
Diabetologia (2006); 49: 1711-172
Assessing the Impact of Visual Acuity on Quality of Life in Individuals With Type 2 Diabetes Using the Short Form-36
Philip M Clarke, Judit Simon, Carole A Cull, Rury R Holman
Diabetes Care 2006; 29: 1506-1511
OBJECTIVE- We sought to ascertain quality-of-life measures and utility values associated with visual acuity in type 2 diabetes.
RESEARCH DESIGN AND METHODS- The Medical Outcome Study Short Form with 36 items (SF-36) was administered to 4,051 individuals with type 2 diabetes who were enrolled in the Lipids in Diabetes Study, and their best attainable vision was determined using an Early Treatment of Diabetic Retinopathy Study chart, expressed as a LogMAR score...
Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75)
The Variable Number of Tandem Repeats Upstream of the Insulin Gene Is a Susceptibility Locus for Latent Autoimmune Diabetes in Adults
Minal Desai, Eleftheria Zeggini, Virginia A. Horton, Katharine R...
Risk Factors for Renal Dysfunction in Type 2 Diabetes : UK Prospective Diabetes Study 74
Ravi Retnakaran, Carole A. Cull, Kerensa I...
Beyond The Boundary
Cutting Edge Issues for Emerging Diabetologists.
Venue: 26-27th October 2006, Eynsham Hall, Oxford
This joint OCDEM and Servier meeting is for specialist registrars who are within two years of completing their training in diabetes and seeking to practice as a consultant...
Oxford University researchers and the Oxford Radcliffe Hospitals Trust will lead one of eight new Local Research Networks for diabetes across the UK, working with hospitals and patients throughout the Thames Valley area to develop prevention methods and treatments for diabetes.
The national Diabetes Research Network, with its eight dedicated Local Research Networks, was announced last week by the Department of Health and the UK Clinical Research Network...
Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective
Rury R. Holman
Metabolism Clinical and Experimental 55 (Suppl 1) (2006) S2-S5
The United Kingdom Prospective Diabetes Study shows sulfonylureas to be an effective first-line therapy for people with type 2 diabetes mellitus...
Lancet 2006; 367:25-26
RR Holman, R Retnakaran, A Farmer and R Stevens
The PROactive study has provided an exploratory estimate of the relative risk reduction attributable to pioglitazone for a composite endpoint of all-cause mortality, non-fatal myocardial infarction, and stroke. Although this secondary endpoint was not prespecified and is not significant when adjusted for multiple testing, it is of interest because of the possibility that the observed 16% relative risk reduction might not be mediated through established macrovascular risk factors such as blood pressure, lipids, and glycaemia...